Adherex Technologies (NASDAQ:FENC) Releases Earnings Results, Beats Expectations By $0.03 EPS

Adherex Technologies (NASDAQ:FENC) issued its earnings results on Thursday. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.03, Zacks reports. The business had revenue of $15.11 million during the quarter, compared to the consensus estimate of $13.90 million. Adherex Technologies had a negative net margin of 17.12% and a negative return on equity of 85.61%.

Here are the key takeaways from Adherex Technologies’ conference call:

• Fennec reported Q1 2026 net product sales of $15.1 million, up about 73% year over year, marking the sixth consecutive quarter of sales growth under the current commercial leadership.
• The company said its commercial push is gaining traction after launching Project Ignite, expanding the field force to 14 new territories and 4 frontline managers and increasing target prescribers from about 1,300 to more than 5,000.
• Operational metrics improved meaningfully, including a 48% quarter-over-quarter increase in completed infusions through Fennec HEARS, conversion rates reaching the company’s 80% benchmark, and adherence running around 80%.
• Management highlighted growing clinical interest in PEDMARK beyond pediatrics, including three investigator-initiated studies and four ASCO abstracts, with potential expansion into AYA and adult patient populations and new tumor types.
• Fennec ended the quarter with $40.1 million in cash and said it generated positive cash flow in Q1, but it also expects Q2 ending cash to be lower and noted it does not anticipate receiving the German milestone payment from partner Norgine.

Adherex Technologies Stock Up 5.5%

Shares of Adherex Technologies stock traded up $0.51 during trading on Friday, reaching $9.75. The company’s stock had a trading volume of 602,528 shares, compared to its average volume of 238,990. The business’s 50-day moving average price is $6.92 and its 200-day moving average price is $7.58. The firm has a market cap of $336.77 million, a PE ratio of -33.62 and a beta of 0.91. Adherex Technologies has a 52 week low of $5.65 and a 52 week high of $10.17.

Insider Activity

In other news, Director Rosty Raykov sold 10,946 shares of the firm’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $6.31, for a total transaction of $69,069.26. Following the transaction, the director directly owned 113,856 shares of the company’s stock, valued at approximately $718,431.36. This trade represents a 8.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.73% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Adherex Technologies

An institutional investor recently bought a new position in Adherex Technologies stock. AQR Capital Management LLC acquired a new position in shares of Adherex Technologies Inc. (NASDAQ:FENC) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,897 shares of the company’s stock, valued at approximately $66,000. Institutional investors own 55.51% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Wedbush reiterated an “outperform” rating and set a $13.00 target price on shares of Adherex Technologies in a research note on Thursday, April 16th. B. Riley Financial began coverage on Adherex Technologies in a report on Thursday, February 12th. They set a “buy” rating and a $16.00 price target for the company. Wall Street Zen upgraded shares of Adherex Technologies from a “hold” rating to a “strong-buy” rating in a report on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Adherex Technologies in a research report on Tuesday, April 21st. Finally, Zacks Research cut shares of Adherex Technologies from a “hold” rating to a “strong sell” rating in a research note on Wednesday, March 25th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Adherex Technologies presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.80.

About Adherex Technologies

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.